(Photo1) Professor Lee Jung-Min in Life Science Department of HGU
Professor Lee Jung-min in Life Science Department of HGU, developed treatment for Leber Congenital Amaurosis, using CRISPR-CAS9 for the first time in the world.
Funded by Korea Bio Grand Challenge of Nation Research Foundation of Korea and Bioyoucell, thesis (title: CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis) was published on Science Advance, Impact factor: 12.8, which has worldwide approval of academic journal publication in October 30th.
Leber Congenital Amaurosis is an eye disorder that affects the retina, causing vision impairment at birth or shortly after birth, and there has been no treatment invented so far.
The research team has proposed a method to correct or remove the mutated gene RPE65 and observed laboratory mouse’s improving vision as its RPE65 was removed or corrected.
Professor Lee Jung-min said, “Additional experiments and data still need to be made yet it is quite significant that a new alternative has been proposed to Leber Congenital Amaurosis treatment.”